Literature DB >> 19474480

Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.

Harel Dahari1, Emi Shudo, Scott J Cotler, Thomas J Layden, Alan S Perelson.   

Abstract

BACKGROUND: Patients infected with hepatitis C virus (HCV) who respond to treatment with interferon-alpha plus ribavirin exhibit biphasic or triphasic viral load decreases. While the rapid first phase is indicative of the effectiveness of therapy in blocking viral production (epsilon), the slope of the final phase (lambda), that is, the second phase in biphasic decreases and the third phase in triphasic decreases, depends on the infected cell loss rate (delta). In standard models, lambda is approximately epsilondelta when the viral clearance rate c>>delta, as has been previously estimated.
METHODS: The relationship among epsilon, delta, lambda and the baseline fraction of HCV-infected hepatocytes (pi) was investigated in a model that included proliferation of hepatocytes.
RESULTS: We found that lambda was not proportional to epsilon, but rather obeyed a complex relationship that could lead to dramatic increases in estimates of delta as epsilon increased. In particular, when epsilon<99%, lambda moderately underestimated delta in patients with a small pi, whereas delta might be up to 10-fold larger than lambda in patients with a large pi. Interestingly, when epsilon>99%, delta approximately lambda regardless of pi.
CONCLUSIONS: Our results indicated that in patients undergoing therapy who achieved a 2 log(10) reduction in viral load (epsilon<99%), previously estimated delta values might represent only a minimal estimate of the infected cell loss rate. Moreover, combining interferon-alpha with new antiviral agents to achieve epsilon>99% should allow for a more accurate estimate of delta in HCV RNA kinetic studies. This might be important when using viral kinetics to estimate the effect of the immune response on viral elimination and the attainment of sustained virological response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474480      PMCID: PMC2874964     

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  18 in total

Review 1.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  In situ distribution of hepatitis C virus replicative-intermediate RNA in hepatic tissue and its correlation with liver disease.

Authors:  M Chang; A P Marquardt; B L Wood; O Williams; S J Cotler; S L Taylor; R L Carithers; D R Gretch
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  HIV-1 infection and low steady state viral loads.

Authors:  Duncan S Callaway; Alan S Perelson
Journal:  Bull Math Biol       Date:  2002-01       Impact factor: 1.758

4.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

5.  Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads.

Authors:  L M Wein; R M D'Amato; A S Perelson
Journal:  J Theor Biol       Date:  1998-05-07       Impact factor: 2.691

6.  Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.

Authors:  Eva Herrmann; Jung-Hun Lee; George Marinos; Marlene Modi; Stefan Zeuzem
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

7.  Dynamics of alanine aminotransferase during hepatitis C virus treatment.

Authors:  Ruy M Ribeiro; Jennifer Layden-Almer; Kimberly A Powers; Thomas J Layden; Alan S Perelson
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Detection of widespread hepatocyte infection in chronic hepatitis C.

Authors:  V Agnello; G Abel; G B Knight; E Muchmore
Journal:  Hepatology       Date:  1998-08       Impact factor: 17.425

10.  Modeling complex decay profiles of hepatitis B virus during antiviral therapy.

Authors:  Harel Dahari; Emi Shudo; Ruy M Ribeiro; Alan S Perelson
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

View more
  16 in total

Review 1.  A perspective on modelling hepatitis C virus infection.

Authors:  J Guedj; L Rong; H Dahari; A S Perelson
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

2.  Optimization of combination therapy for chronic myeloid leukemia with dosing constraints.

Authors:  Helen Moore; Lewis Strauss; Urszula Ledzewicz
Journal:  J Math Biol       Date:  2018-07-10       Impact factor: 2.259

3.  Understanding silibinin's modes of action against HCV using viral kinetic modeling.

Authors:  Jeremie Guedj; Harel Dahari; Ralf T Pohl; Peter Ferenci; Alan S Perelson
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

4.  Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Authors:  Harel Dahari; Jeremie Guedj; Alan S Perelson; Thomas J Layden
Journal:  Curr Hepat Rep       Date:  2011-07-02

5.  Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.

Authors:  Harel Dahari; Evaldo S Affonso de Araujo; Bart L Haagmans; Thomas J Layden; Scott J Cotler; Antonio A Barone; Avidan U Neumann
Journal:  J Hepatol       Date:  2010-05-27       Impact factor: 25.083

Review 6.  Modelling hepatitis C therapy--predicting effects of treatment.

Authors:  Alan S Perelson; Jeremie Guedj
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-30       Impact factor: 46.802

7.  Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

Authors:  Evaldo Stanislau Affonso de Araujo; Harel Dahari; Scott J Cotler; Thomas J Layden; Avidan U Neumann; Carlos Eduardo Melo; Antonio Alci Barone
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

8.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.

Authors:  Jeremie Guedj; Yaron Rotman; Scott J Cotler; Christopher Koh; Peter Schmid; Jeff Albrecht; Vanessa Haynes-Williams; T Jake Liang; Jay H Hoofnagle; Theo Heller; Harel Dahari
Journal:  Hepatology       Date:  2014-10-27       Impact factor: 17.425

9.  Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Authors:  Laetitia Canini; Swati DebRoy; Zoe Mariño; Jessica M Conway; Gonzalo Crespo; Miquel Navasa; Massimo D'Amato; Peter Ferenci; Scott J Cotler; Xavier Forns; Alan S Perelson; Harel Dahari
Journal:  Antivir Ther       Date:  2014-06-10

Review 10.  Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Authors:  Anushree Chatterjee; Jeremie Guedj; Alan S Perelson
Journal:  Antivir Ther       Date:  2012-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.